$MYGN
MYRIAD GENETICS INC Stock $mygn

$mygn Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312515032873 Filed on February 04, 2015

Income Statement

Concept	2014 Q4	2014 Q2	2013 Q4
Revenue	$184.4M	$188.8M	$204.1M
YoY Change	-9.63%	8.44%	36.82%
Cost Of Revenue	$35.10M	$31.00M	$22.76M
YoY Change	54.25%	40.27%	46.18%
Gross Profit	$149.3M	$157.8M	$181.3M
YoY Change	-17.65%	3.82%	35.73%
Gross Profit Margin	80.97%	83.58%	88.85%
Selling, General & Admin	$92.70M	$84.30M	$77.84M
YoY Change	19.09%	17.9%	30.69%
% of Gross Profit	62.09%	53.42%	42.93%
Research & Development	$17.50M	$20.20M	$17.09M
YoY Change	2.4%	38.36%	21.15%
% of Gross Profit	11.72%	12.8%	9.43%
Depreciation & Amortization	$2.900M	$5.500M	$2.400M
YoY Change	20.83%	139.13%	4.35%
% of Gross Profit	1.94%	3.49%	1.32%
Operating Expenses	$110.2M	$104.5M	$94.93M
YoY Change	16.09%	21.37%	28.86%
Operating Profit	$36.30M	$53.30M	$83.00M
YoY Change	-56.26%	-19.12%	49.32%
Interest Expense	$100.0K	$200.0K	$1.300M
YoY Change	-92.31%	-84.62%	-7.14%
% of Operating Profit	0.28%	0.38%	1.57%
Other Income/Expense, Net	$1.600M	-$900.0K	$1.145M
YoY Change	39.74%		-18.16%
Pretax Income	$37.90M	$52.60M	$84.14M
YoY Change	-54.96%	-21.73%	47.66%
Income Tax	$13.90M	$18.90M	$33.78M
% Of Pretax Income	36.68%	35.93%	40.15%
Net Earnings	$24.00M	$33.60M	$50.36M
YoY Change	-52.34%	-23.81%	43.74%
Net Earnings / Revenue	13.02%	17.8%	24.68%
Basic Earnings Per Share	$0.33		$0.67
Diluted Earnings Per Share	$0.32	$432.4K	$0.66
COMMON SHARES
Basic Shares Outstanding	72.50M shares	74.82M shares	75.07M shares
Diluted Shares Outstanding	75.40M shares		76.83M shares

Balance Sheet

Concept	2014 Q4	2014 Q2	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$165.1M	$186.5M	$353.6M
YoY Change	-53.31%	-49.91%	-1.39%
Cash & Equivalents	$59.70M	$64.80M	$71.60M
Short-Term Investments	$105.4M	$121.6M	$282.0M
Other Short-Term Assets	$48.30M	$26.90M	$13.30M
YoY Change	263.16%	177.32%	13.68%
Inventory	$20.17M	$23.90M
Prepaid Expenses	$7.694M	$6.921M	$4.237M
Receivables	$81.22M	$81.90M	$84.14M
Other Receivables	$5.331M	$3.200M	$3.500M
Total Short-Term Assets	$320.1M	$322.4M	$454.5M
YoY Change	-29.57%	-33.39%	-0.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.46M	$34.60M	$31.31M
YoY Change	48.37%	25.35%	14.76%
Goodwill	$169.2M	$169.2M	$56.85M
YoY Change	197.59%	197.36%	0.0%
Intangibles	$198.8M	$205.3M	$12.84M
YoY Change	1448.26%	1440.14%	-6.39%
Long-Term Investments	$42.30M	$84.10M	$135.2M
YoY Change	-68.71%	-47.01%	23.36%
Other Assets	$5.000M	$5.000M	$43.00M
YoY Change	-88.37%	-61.54%	31.9%
Total Long-Term Assets	$461.8M	$501.4M	$302.2M
YoY Change	52.81%	56.77%	16.04%
TOTAL ASSETS
Total Short-Term Assets	$320.1M	$322.4M	$454.5M
Total Long-Term Assets	$461.8M	$501.4M	$302.2M
Total Assets	$781.9M	$823.8M	$756.7M
YoY Change	3.33%	2.49%	5.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.83M	$23.10M	$17.60M
YoY Change	-4.34%	27.4%	29.62%
Accrued Expenses	$41.18M	$56.40M	$45.84M
YoY Change	-10.17%	27.22%	57.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$59.84M	$80.60M	$67.39M
YoY Change	-11.21%	24.94%	48.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.30M	$0.00	$13.30M
YoY Change	90.23%	-100.0%	31.68%
Total Long-Term Liabilities	$25.30M	$0.00	$13.30M
YoY Change	90.23%	-100.0%	31.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.84M	$80.60M	$67.39M
Total Long-Term Liabilities	$25.30M	$0.00	$13.30M
Total Liabilities	$87.61M	$104.8M	$80.71M
YoY Change	8.55%	39.31%	45.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.98M	$2.000M	$11.60M
YoY Change	-418.67%	-93.52%	-371.61%
Common Stock	$719.0K	$700.0K	$740.0K
YoY Change	-2.84%	-13.15%	-8.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$694.2M	$719.0M	$676.0M
YoY Change
Total Liabilities & Shareholders Equity	$781.9M	$823.8M	$756.7M
YoY Change	3.33%	2.49%	5.42%

Cashflow Statement

Concept	2014 Q4	2014 Q2	2013 Q4
OPERATING ACTIVITIES
Net Income	$24.00M	$33.60M	$50.36M
YoY Change	-52.34%	-23.81%	43.74%
Depreciation, Depletion And Amortization	$2.900M	$5.500M	$2.400M
YoY Change	20.83%	139.13%	4.35%
Cash From Operating Activities	$52.60M	$40.90M	$47.50M
YoY Change	10.74%	-35.08%	114.93%
INVESTING ACTIVITIES
Capital Expenditures	-$5.900M	-$4.600M	-$2.800M
YoY Change	110.71%	64.29%	-37.78%
Acquisitions
YoY Change
Other Investing Activities	-$2.800M	-$14.30M	$13.60M
YoY Change	-120.59%	-82.52%	-146.1%
Cash From Investing Activities	-$8.800M	-$18.90M	$10.80M
YoY Change	-181.48%	-77.66%	-131.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-52.20M	-42.10M	-71.70M
YoY Change	-27.2%	-416.54%	368.63%
NET CHANGE
Cash From Operating Activities	52.60M	40.90M	47.50M
Cash From Investing Activities	-8.800M	-18.90M	10.80M
Cash From Financing Activities	-52.20M	-42.10M	-71.70M
Net Change In Cash	-8.400M	-20.10M	-13.40M
YoY Change	-37.31%	142.17%	-50.74%
FREE CASH FLOW
Cash From Operating Activities	$52.60M	$40.90M	$47.50M
Capital Expenditures	-$5.900M	-$4.600M	-$2.800M
Free Cash Flow	$58.50M	$45.50M	$50.30M
YoY Change	16.3%	-30.85%	89.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104073000
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73497000	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73497000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.30
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14238603	shares
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	65013000
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	80578000
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	735000
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1515000
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	23078000
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2004000
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56410000
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	718998000
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	823814000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8238000
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	717774000
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1090000
CY2014Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24238000
CY2014Q2	us-gaap	Liabilities Liabilities	104816000
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8968000
CY2014Q2	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	383000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64821000
CY2014Q2	us-gaap	Goodwill Goodwill	169181000
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34594000
CY2014Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	225405000
CY2014Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	270586000
CY2014Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4800000
CY2014Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	213550000
CY2014Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	3180000
CY2014Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	121641000
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	99607000
CY2014Q2	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000
CY2014Q2	us-gaap	Assets Assets	823814000
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	6445000
CY2014Q2	us-gaap	Inventory Net InventoryNet	23919000
CY2014Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	84124000
CY2014Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3770000
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	81297000
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	270224000
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	205312000
CY2014Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	18922000
CY2014Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	80685000
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000000
CY2014Q2	us-gaap	Prepaid Taxes PrepaidTaxes	13609000
CY2014Q2	us-gaap	Assets Current AssetsCurrent	322423000
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6921000
CY2014Q2	mygn	Indefinite Lived Intangible Assets Accumulated Amortization IndefiniteLivedIntangibleAssetsAccumulatedAmortization
CY2014Q2	mygn	Indefinite Lived Intangible Assets Gross Excluding Goodwill IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill	4800000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71599000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71518000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71518000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	37.84
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	22.64
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.48
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1100183	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13111742	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	8803382	shares
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	67804000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	59837000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	719000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4182000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16833000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36975000
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2450000
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41180000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	694241000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	781854000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12723000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	734679000
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1824000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	25326000
CY2014Q4	us-gaap	Liabilities Liabilities	87613000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7929000
CY2014Q4	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	148000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59709000
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	28700000
CY2014Q4	us-gaap	Goodwill Goodwill	169181000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46458000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	22138000
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	150405000
CY2014Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	229467000
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	229553000
CY2014Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4800000
CY2014Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	211550000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	31300000
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	105406000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	114262000
CY2014Q4	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	62000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	105370000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	42300000
CY2014Q4	us-gaap	Cost Method Investments CostMethodInvestments	5000000
CY2014Q4	us-gaap	Assets Assets	781854000
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	12813000
CY2014Q4	us-gaap	Inventory Net InventoryNet	20173000
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	42300000
CY2014Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	5331000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	81222000
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	229467000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	229553000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	198827000
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	18913000
CY2014Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	95349000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5000000
CY2014Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5602000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	320088000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	105406000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	42250000
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7694000
CY2014Q4	mygn	Indefinite Lived Intangible Assets Accumulated Amortization IndefiniteLivedIntangibleAssetsAccumulatedAmortization
CY2014Q4	mygn	Indefinite Lived Intangible Assets Gross Excluding Goodwill IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill	4800000
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71118496	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.33
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1989000	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.37	pure
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	138031000
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	1.17
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79312000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.37
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	1.20
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7136000	shares
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	2600000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77323000	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	392000
	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	151477000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	8098000
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	17383000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	592000
	us-gaap	Operating Income Loss OperatingIncomeLoss	165903000
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	1333000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-40000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	106755000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2068000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	172000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1826000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	167971000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	92804000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	180124000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-623000
	us-gaap	Revenues Revenues	406527000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	102661000
	us-gaap	Net Income Loss NetIncomeLoss	105825000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2691000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11597000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	389144000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	538000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1807000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	430051000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13792000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1909000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33893000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	155119000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	592000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	21793000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	488000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-32474000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62146000
	us-gaap	Cost Of Revenue CostOfRevenue	44194000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4811000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-173170000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1510000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2273000
	us-gaap	Costs And Expenses CostsAndExpenses	240624000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	113032000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	392000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-536000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6362000
	us-gaap	Share Based Compensation ShareBasedCompensation	13792000
	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	55036000
	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	125088000
	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	7418000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.53
	dei	Entity Registrant Name EntityRegistrantName	MYRIAD GENETICS INC
	dei	Trading Symbol TradingSymbol	MYGN
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3140000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	79450	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	19.91
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.37	pure
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	59578000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	37.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left"><u>Basis of Presentation</u></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2014, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014. Operating results for the three and six months ended December 31, 2014 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Certain reclassifications have been made to prior period amounts to conform to the current period presentation. For the six months ended December 31, 2013, a reclassification from proceeds from maturities and sales of marketable securities was made to the effect of foreign exchange rates on cash and cash equivalents in the condensed consolidated statement of cash flows to conform to current-year presentation.</p> </div>
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1179633	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	25.75
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75755000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	254087	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	37.17
	dei	Entity Central Index Key EntityCentralIndexKey	0000899923
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.55
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	1088000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72615000	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2390000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	21603000
	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	62262000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39000	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	Segment
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	873774	shares
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	17448000
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	9574000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	2629000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3746000
	us-gaap	Operating Income Loss OperatingIncomeLoss	62262000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	16000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	37346000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1556000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1561000
	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-8007000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1891000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	63818000
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	40013000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	103952000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1416000
	us-gaap	Revenues Revenues	353230000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22623000
	us-gaap	Net Income Loss NetIncomeLoss	40013000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	140000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13886000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	343656000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-277000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	773000
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	535000
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	353230000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19028000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	734000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40116000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	178135000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2629000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	13959000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6485000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5112000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23805000
	us-gaap	Cost Of Revenue CostOfRevenue	67847000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11990000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-81128000
	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15233000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	18828000
	us-gaap	Costs And Expenses CostsAndExpenses	290968000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80502000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-2390000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6245000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	20195000
	us-gaap	Share Based Compensation ShareBasedCompensation	19028000
	mygn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Canceled In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledInPeriodWeightedAverageGrantDateFairValue	38.12
	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	24960000
	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	78992000
	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	4870000
CY2014Q3	mygn	Number Of Restricted Stock Units Issuance As Percentage Of Stock Options Granted NumberOfRestrictedStockUnitsIssuanceAsPercentageOfStockOptionsGranted	0.3333	pure
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2013Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1755000	shares
CY2013Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.40	pure
CY2013Q4	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.62
CY2013Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76825000	shares
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2013Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	77840000
CY2013Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	244000
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33784000
CY2013Q4	us-gaap	Cost Of Revenue CostOfRevenue	22755000
CY2013Q4	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.63
CY2013Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8500000	shares
CY2013Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75070000	shares
CY2013Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-112000
CY2013Q4	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	80474000
CY2013Q4	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	7902000
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	82999000
CY2013Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	50501000
CY2013Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1145000
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	84144000
CY2013Q4	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	47433000
CY2013Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-185000
CY2013Q4	us-gaap	Revenues Revenues	204060000
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	50360000
CY2013Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	1330000
CY2013Q4	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	196158000
CY2013Q4	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	253000
CY2013Q4	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	225700000
CY2013Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6857000
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17090000
CY2013Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2438000
CY2013Q4	us-gaap	Costs And Expenses CostsAndExpenses	121061000
CY2013Q4	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	25096000
CY2013Q4	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	52713000
CY2013Q4	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	3376000
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2014Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2934000	shares
CY2014Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.37	pure
CY2014Q4	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.32
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75401000	shares
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2014Q4	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.33
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2014Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	844000	shares
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72467000	shares
CY2014Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1669000
CY2014Q4	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	36342000
CY2014Q4	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	5244000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	36342000
CY2014Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22217000
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1598000
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	37940000
CY2014Q4	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	24031000
CY2014Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1513000
CY2014Q4	us-gaap	Revenues Revenues	184393000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	24031000
CY2014Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	85000
CY2014Q4	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	179149000
CY2014Q4	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-145000
CY2014Q4	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	184393000
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12147000
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17504000
CY2014Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	92695000
CY2014Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3135000
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13909000
CY2014Q4	us-gaap	Cost Of Revenue CostOfRevenue	35050000
CY2014Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6036000
CY2014Q4	us-gaap	Costs And Expenses CostsAndExpenses	148051000
CY2014Q4	mygn	Amount Of Reduction In Common Stock As Result Of Stock Repurchases AmountOfReductionInCommonStockAsResultOfStockRepurchases	14765000
CY2014Q4	mygn	Amount Charged To Retained Earnings As Result Of Stock Repurchases AmountChargedToRetainedEarningsAsResultOfStockRepurchases	43559000
CY2014Q4	mygn	Cost Of Pharmaceutical And Clinical Services CostOfPharmaceuticalAndClinicalServices	2802000

Files In Submission

Name	View Source	Status
0001193125-15-032873-index-headers.html	Edgar Link	pending
0001193125-15-032873-index.html	Edgar Link	pending
0001193125-15-032873.txt	Edgar Link	pending
0001193125-15-032873-xbrl.zip	Edgar Link	pending
d845963d10q.htm	Edgar Link	pending
d845963dex101.htm	Edgar Link	pending
d845963dex311.htm	Edgar Link	pending
d845963dex312.htm	Edgar Link	pending
d845963dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mygn-20141231.xml	Edgar Link	completed
mygn-20141231.xsd	Edgar Link	pending
mygn-20141231_cal.xml	Edgar Link	unprocessable
mygn-20141231_def.xml	Edgar Link	unprocessable
mygn-20141231_lab.xml	Edgar Link	unprocessable
mygn-20141231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYGN
MYRIAD GENETICS INC Stock $mygn

2014 Q4 Form 10-Q Financial Statement

#000119312515032873 Filed on February 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN MYRIAD GENETICS INC Stock $mygn

2014 Q4 Form 10-Q Financial Statement

#000119312515032873 Filed on February 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYGN
MYRIAD GENETICS INC Stock $mygn